Jackson Grant Investment Advisers’s Myriad Genetics MYGN Stock Holding History

Jackson Grant Investment Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,032	Closed	-$20K	–	331
2022 Q3	$20K	Hold	1,032	–	–	0.01%	255
2022 Q2	$19K	Hold	1,032	–	–	0.01%	269
2022 Q1	$26K	Hold	1,032	–	–	0.01%	259
2021 Q4	$28K	Hold	1,032	–	–	0.01%	214
2021 Q3	$33K	Hold	1,032	–	–	0.01%	247
2021 Q2	$32K	Hold	1,032	–	–	0.01%	250
2021 Q1	$31K	Hold	1,032	–	–	0.01%	245
2020 Q4	$20K	Buy	+1,032	New	+$16.7K	0.01%	257

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Jackson Grant Investment Advisers's MYGN Position: Q4 2022 in Review

Jackson Grant Investment Advisers sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 1,032 shares — an estimated $20K sold.

Jackson Grant Investment Advisers first reported a position in MYGN in Q4 2020 and held it in 8 quarters. The position peaked at $33K in Q3 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

Jackson Grant Investment Advisers reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
Jackson Grant Investment Advisers sold 1,032 Myriad Genetics shares in Q4 2022, an estimated $20K.
Jackson Grant Investment Advisers first reported a position in Myriad Genetics in Q4 2020 and held it in 8 quarters.
Jackson Grant Investment Advisers's Myriad Genetics position peaked at $33K in Q3 2021.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on Jackson Grant Investment Advisers's 13F filing for Q4 2022, filed 26 Jan 2023.